Your Health and Fitness Partner: Androxal & FitHub

We are also excited to expand our scope by including valuable information on Androxal, a potent medication beneficial in various medical conditions. This remarkable drug, derived from the testosterone molecule, has made its mark significantly in the field of endocrinology. Patients and medical professionals can rely on our comprehensive, unbiased, and scientifically grounded content on Androxal for gaining a robust understanding of its uses, side effects, and the latest studies related to it. We understand the necessity of accurate information when it comes to medication. Our newly launched section dedicated to Androxal aims at not only educating the readers about its nuances but also at contributing beneficially to their wellbeing. Stay tuned for insightful articles unraveling the potential of Androxal in medical science.

Sitemap | Policies | Feedback    
 About the Journal
Editorial Board
Journal Subscription
Instructions for Authors
E-mail Alerts
Forthcoming Events
Advertise with Us
Contact Us
Article Options
Printer Friendly Version
Search Pubmed for
Search Google Scholar for
Article Statistics
Bookmark and Share
Prevalence and Characteristics of Venous Thromboembolism in Outpatients of Ulcerative Colitis: A Single-Center experience
Brij Sharma1, Neetu Sharma2, Vineeta Sharma3, Vishal Bodh1, Rajesh Sharma1, Rajesh Kumar1, Sidhant Sharma4, Harmandeep Singh Thabal1, Ashish Chauhan1
1Department of Gastroenterology, 2Department of Physiology, 3Department of Microbiology, Indira Gandhi Medical College, Shimla, India. 4MBBS Student, Anna Medical College, Mauritius. 

Corresponding Author
Dr. Ashish Chauhan


Background: Venous thromboembolism (VTE) is a known complication in patients with inflammatory bowel disease (IBD), including ulcerative colitis (UC). This study aimed to investigate the prevalence and clinical characteristics of VTE in patients with UC, and to identify potential risk factors for VTE in this population.
Methods: This was a single-centre retrospective cohort study involving 167 patients with UC from 2015 and 2022. Patient demographics, disease characteristics, medication history, and VTE events were extracted from outpatient records. 
Results: The study included 167 patients, of which 58.68% were males. The prevalence of VTE in outpatients with UC was 3% (n=5), with four patients having deep venous thrombosis (DVT), two having cerebral venous thrombosis (CVT) and one patient having both CVT and DVT. The mean age of patients with VTE was 48 ± 18.75 years and all patients were females. Four patients had history of acute severe colitis in past and were treated with steroids. There was no mortality in patients with VTE during the study period, and none underwent colectomy. Prothrombotic work up was negative in all the patients (4/4). The median duration of follow-up was five years, and median duration between IBD diagnosis and occurrence of VTE was three years.
Conclusion: This study found a prevalence of 3% in a cohort of UC patients with milder disease. Past history of acute severe colitis and steroid use were seen in patients with UC who developed VTE (4/5), though no statistically significant association could be found due to small sample size.